Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function
Edvinas Cerniauskas, Marzena Kurzawa‐Akanbi, Long Xie, Dean Hallam, Marina Moya Molina, Kathryn White, David Steel, Mary K. Doherty, Phil D. Whitfield, Jumana Y. Al‐Aama, Lyle Armstrong, David Kavanagh, John D. Lambris, Viktor I. Korolchuk, Claire L. Harris, Majlinda Lako
Abstract
Abstract Age-related macular degeneration (AMD) is a multifactorial disease, which is characterized by loss of central vision, affecting one in three people by the age of 75. The Y402H polymorphism in the complement factor H (CFH) gene significantly increases the risk of AMD. We show that Y402H-AMD-patient-specific retinal pigment epithelium (RPE) cells are characterized by a significant reduction in the number of melanosomes, an increased number of swollen lysosome-like-vesicles with fragile membranes, Cathepsin D leakage into drusen-like deposits and reduced lysosomal function. The turnover of C3 is increased significantly in high-risk RPE cells, resulting in higher internalization and deposition of the terminal complement complex C5b-9 at the lysosomes. Inhibition of C3 processing via the compstatin analogue Cp40 reverses the disease phenotypes by relieving the lysosomes of their overburden and restoring their function. These findings suggest that modulation of the complement system represents a useful therapeutic approach for AMD patients associated with complement dysregulation. Significance statement Currently, there is no treatment for dry age-related macular degeneration (AMD), which comprises the majority of AMD pathology. In a collaborative effort, this study describes a novel link between uncontrolled complement activation and autophagy-lysosome axis, which is caused by increased deposition of the terminal attack complex C5b-9 at the lysosomes, leading to their overburdening and malfunction. Using an inhibitor of C3 processing, Cp40, this study shows that all the disease phenotypes are reversed, relieving the lysosomes of their overburden and restoring their function. These findings suggest that modulation of the complement system represents a useful therapeutic approach for AMD patients associated with complement dysregulation.